四川科瑞德

Sichuan Kered Pharmaceutical is a specialized pharmaceutical company based in Luzhou, China, focusing on the development and commercialization of therapies for the central nervous system (CNS). The company maintains a robust portfolio of high-barrier generic drugs and innovative small molecules in the fields of anesthesia, analgesia, and psychiatry. Kered operates a fully integrated value chain encompassing research and development, active pharmaceutical ingredient (API) production, and finished dosage form manufacturing. Its commercial success is driven by key products such as dexmedetomidine and ropivacaine, while its clinical pipeline targets significant unmet needs in depression and anxiety. The company is recognized as a leading CNS player in the Chinese domestic market with expanding research capabilities in Chengdu.